AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12401580 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study 10460126 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedaling at 60 rpm
Number of subjects: 11
Study 10460126 — intervention group
Group type: EXPERIMENTAL
Intervention: Kicking dominant leg
Number of subjects: 11
Study 10460126 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dominant leg
Number of subjects: 11
Study 10460126 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall subject sample
Number of subjects: 11
Study 10460126 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual subjects
Number of subjects: 11
Study 7798579 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat controlled diet plus 20 g corn bran supplement
Number of subjects: 29
Study 7798579 — intervention group
Group type: COMPARATOR
Intervention: Low-fat controlled diet plus 20 g wheat bran supplement
Number of subjects: 29
Study 7798579 — intervention group
Group type: COMPARATOR
Intervention: Low-fat controlled diet
Number of subjects: 29
Study 2086820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CXM-AX) 250 mg t.i.d. for 3-7 days
Number of subjects: 251
Study 2086820 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (CCL) 250 mg t.i.d. for 3-7 days
Number of subjects: 251
Study 2086820 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (CXM-AX)
Number of subjects: 251
Study 2086820 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor (CCL)
Number of subjects: 251
Study 765515 — intervention group
Group type: EXPERIMENTAL
Intervention: 600,000 units of penicillin G benzathine
Number of subjects: 400
Study 765515 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 million units of penicillin G benzathine
Number of subjects: 400
Study 765515 — intervention group
Group type: EXPERIMENTAL
Intervention: 600,000 units of penicillin G benzathine and 600,000 units of penicillin G procaine
Number of subjects: 400
Study 765515 — intervention group
Group type: EXPERIMENTAL
Intervention: 900,000 units of penicillin G benzathine and 300,000 units of penicillin G procaine
Number of subjects: 400
Study 31027892 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with Tacrolimus (EVR/TAC)
Number of subjects: 338
Study 31027892 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with Cyclosporine (EVR/CsA)
Number of subjects: 338
Study 31027892 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolic Acid with Tacrolimus (MPA/TAC)
Number of subjects: 338
Study 31027892 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 338
Study 28679681 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg)
Number of subjects: 19
Study 28679681 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 19
Study 26115983 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel four quadrant technique
Number of subjects: 90
Study 26115983 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptic feedback
Number of subjects: 90
Study 26115983 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar cutting guide
Number of subjects: 90
Study 24118640 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg plus metformin 1000 mg bid
Number of subjects: 566
Study 24118640 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin 2.5 mg plus metformin 500 mg bid
Number of subjects: 566
Study 24118640 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg bid
Number of subjects: 566
Study 24118640 — intervention group
Group type: COMPARATOR
Intervention: Metformin 500 mg bid
Number of subjects: 566
Study 24118640 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin 5 mg qd
Number of subjects: 566
Study 24118640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 566
Study 16451766 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse (CHX)
Number of subjects: 63
Study 16451766 — intervention group
Group type: COMPARATOR
Intervention: Herbal rinse (HBR)
Number of subjects: 63
Study 16451766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 15102334 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed Length of Stay (LOS) for patients with inefficient care
Number of subjects: 374
Study 15102334 — intervention group
Group type: EXPERIMENTAL
Intervention: Observed Length of Stay (LOS) for patients with acceptable efficiency
Number of subjects: 374
Study 15102334 — intervention group
Group type: COMPARATOR
Intervention: Function for predicting LOS
Number of subjects: 374
Study 15102334 — intervention group
Group type: COMPARATOR
Intervention: Age as a predictor of LOS
Number of subjects: 374
Study 15102334 — intervention group
Group type: COMPARATOR
Intervention: Response to treatment as a predictor of LOS
Number of subjects: 374
Study 15102334 — intervention group
Group type: COMPARATOR
Intervention: Dummy for personality disorders as a predictor of LOS
Number of subjects: 374
Study 15102334 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT) as a predictor of LOS
Number of subjects: 374
Study 15102334 — intervention group
Group type: COMPARATOR
Intervention: Factor for sexual and/or eating symptoms as a predictor of LOS
Number of subjects: 374
Study 15102334 — intervention group
Group type: COMPARATOR
Intervention: Factor for psychotic symptoms as a predictor of LOS
Number of subjects: 374
Study 15102334 — intervention group
Group type: COMPARATOR
Intervention: ROC curve for detecting inefficiencies
Number of subjects: 374
Study 10939601 — intervention group
Group type: COMPARATOR
Intervention: 5-FU plus FA (arm A)
Number of subjects: 48
Study 10939601 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU plus FA plus IFO (arm B)
Number of subjects: 48
Study 8729156 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and waist-to-hip ratio (WHR)
Number of subjects: 869
Study 8729156 — intervention group
Group type: COMPARATOR
Intervention: Age and other factors combined
Number of subjects: 869
Study 8729156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethnicity (African-American and Hispanic women)
Number of subjects: 869
Study 8729156 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intake, cigarette smoking, physical activity, parity, education, and income
Number of subjects: 869
Study 8729156 — intervention group
Group type: COMPARATOR
Intervention: Age
Number of subjects: 869
Study 1422487 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (Allo‐BMT)
Number of subjects: 40
Study 1422487 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation (Auto‐BMT)
Number of subjects: 40
Study 1422487 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (Chemo)
Number of subjects: 40
Study 2998786 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Metoprolol (beta 1‐selective)
Number of subjects: 63
Study 2998786 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg Propranolol (non‐selective)
Number of subjects: 63
Study 2998786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 30449521 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based learning module (Radiopaedia.org)
Number of subjects: 47
Study 30449521 — intervention group
Group type: COMPARATOR
Intervention: Traditional learning material
Number of subjects: 47
Study 28820949 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic cartilage implant MTPJ1 hemiarthroplasty
Number of subjects: 176
Study 28820949 — intervention group
Group type: COMPARATOR
Intervention: First metatarsophalangeal joint arthrodesis
Number of subjects: 176
Study 25867139 — intervention group
Group type: EXPERIMENTAL
Intervention: elpamotide + gemcitabine
Number of subjects: 153
Study 25867139 — intervention group
Group type: COMPARATOR
Intervention: placebo + gemcitabine
Number of subjects: 153
Study 24499493 — intervention group
Group type: EXPERIMENTAL
Intervention: NRL001 5 mg, 7.5 mg, or 10 mg in 1 or 2 g suppositories
Number of subjects: 48
Study 24499493 — intervention group
Group type: EXPERIMENTAL
Intervention: NRL001 10 mg, 12.5 mg, or 15 mg in 1 or 2 g suppositories
Number of subjects: 48
Study 24499493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 24499493 — intervention group
Group type: EXPERIMENTAL
Intervention: NRL001 doses (1 g and 2 g)
Number of subjects: 48
Study 24499493 — intervention group
Group type: EXPERIMENTAL
Intervention: NRL001 doses
Number of subjects: 48
Study 20927112 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1021
Study 20927112 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 1021
Study 19345644 — intervention group
Group type: EXPERIMENTAL
Intervention: EVT 201 1.5 mg
Number of subjects: 75
Study 19345644 — intervention group
Group type: EXPERIMENTAL
Intervention: EVT 201 2.5 mg
Number of subjects: 75
Study 19345644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 17351300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkles 12.5 mg ferrous fumarate
Number of subjects: 432
Study 17351300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkles 20 mg ferrous fumarate
Number of subjects: 432
Study 17351300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkles 30 mg ferrous fumarate
Number of subjects: 432
Study 17351300 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprinkles 20 mg micronized ferric pyrophosphate
Number of subjects: 432
Study 17351300 — intervention group
Group type: COMPARATOR
Intervention: DROPS 20 mg ferrous glycine sulphate
Number of subjects: 432
Study 15364158 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprandial dosing of BIAsp 30 (b.i.d. injections before meals)
Number of subjects: 93
Study 15364158 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial dosing of BIAsp 30 (b.i.d. injections after meals)
Number of subjects: 93
Study 15364158 — intervention group
Group type: COMPARATOR
Intervention: Postprandial dosing of BIAsp 30
Number of subjects: 93
Study 15364158 — intervention group
Group type: COMPARATOR
Intervention: Preprandial dosing of BIAsp 30
Number of subjects: 93
Study 15364158 — intervention group
Group type: COMPARATOR
Intervention: Postprandial injection
Number of subjects: 93
Study 11454372 — intervention group
Group type: COMPARATOR
Intervention: Traditional epidural (n=353)
Number of subjects: 1054
Study 11454372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose combined spinal epidural (n=351)
Number of subjects: 1054
Study 11454372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose infusion epidural (n=350)
Number of subjects: 1054
Study 11454372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose techniques
Number of subjects: 1054
Study 11454372 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose infusion group
Number of subjects: 1054
Study 9498439 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (60-mg retinol equivalent, 200,000 IU)
Number of subjects: 120
Study 9498439 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 7989683 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration anesthesia administered into the incised edges of the wound
Number of subjects: 81
Study 7989683 — intervention group
Group type: COMPARATOR
Intervention: Infiltration anesthesia administered into the skin surrounding the wound
Number of subjects: 81
Study 2563896 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (coronary arteriography followed by prophylactic PTCA)
Number of subjects: 3262
Study 2563896 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (PTCA only if ischemia occurred)
Number of subjects: 3262
Study 2563896 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metoprolol (15 mg immediately, followed by oral metoprolol)
Number of subjects: 3262
Study 2563896 — intervention group
Group type: COMPARATOR
Intervention: Deferred oral beta-blockade (started on day 6)
Number of subjects: 3262
Study 31429625 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 16
Study 31429625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30650202 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive randomization ratio change
Number of subjects: 0
Study 30650202 — intervention group
Group type: EXPERIMENTAL
Intervention: Sample size reestimation
Number of subjects: 0
Study 30650202 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical adjustment for final analysis
Number of subjects: 0
Study 30650202 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonproportional increase in sample size
Number of subjects: 0
Study 29078199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) encompassing three individual sessions and regular home practice
Number of subjects: 74
Study 29078199 — intervention group
Group type: COMPARATOR
Intervention: Control condition combining psycho-educational components and regular rest periods
Number of subjects: 74
Study 29078199 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI)
Number of subjects: 74
Study 25556976 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly (AOM) 400 mg
Number of subjects: 502
Study 25556976 — intervention group
Group type: COMPARATOR
Intervention: Oral aripiprazole (6-24 mg/day)
Number of subjects: 502
Study 23995469 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICES intervention (Web-based, multimedia educational intervention)
Number of subjects: 234
Study 23995469 — intervention group
Group type: COMPARATOR
Intervention: e-Book (attention-control usual care intervention)
Number of subjects: 234
Study 21756809 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC (docetaxel + pirarubicin + cyclophosphamide)
Number of subjects: 139
Study 21756809 — intervention group
Group type: COMPARATOR
Intervention: TEC (docetaxel + epirubicin + cyclophosphamide)
Number of subjects: 139
Study 21756809 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF (cyclophosphamide + pirarubicin + fluorouracil)
Number of subjects: 139
Study 21756809 — intervention group
Group type: COMPARATOR
Intervention: CEF (cyclophosphamide + epirubicin + fluorouracil)
Number of subjects: 139
Study 19500396 — intervention group
Group type: EXPERIMENTAL
Intervention: CT drainage for group A (pseudocysts > 1l)
Number of subjects: 27
Study 19500396 — intervention group
Group type: COMPARATOR
Intervention: Control group B (pseudocysts < 1l)
Number of subjects: 27
Study 17117016 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir 500 mg twice a day
Number of subjects: 60
Study 14665607 — intervention group
Group type: EXPERIMENTAL
Intervention: MVAC
Number of subjects: 220
Study 14665607 — intervention group
Group type: COMPARATOR
Intervention: DC
Number of subjects: 220
Study 11069512 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface microscopy education intervention
Number of subjects: 74
Study 11069512 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 74
Study 9272926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) via Turbuhaler (TH)
Number of subjects: 48
Study 9272926 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) via pressurized metered-dose inhaler (pMDI)
Number of subjects: 48
Study 9272926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 8392270 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% bladder filling
Number of subjects: 71
Study 8392270 — intervention group
Group type: COMPARATOR
Intervention: 75% bladder filling
Number of subjects: 71
Study 2942747 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 12
Study 2942747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30646030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction diet (500-600 kcal/d for 2 nonconsecutive days per week)
Number of subjects: 137
Study 30646030 — intervention group
Group type: COMPARATOR
Intervention: Continuous energy restriction diet (1200-1500 kcal/d for 7 days per week)
Number of subjects: 137
Study 30646030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction diet
Number of subjects: 137
Study 30646030 — intervention group
Group type: COMPARATOR
Intervention: Continuous energy restriction diet
Number of subjects: 137
Study 27716211 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention (SMI) with personalised risk information
Number of subjects: 211
Study 27716211 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management intervention (SMI) plus risk group (Caucasian participants, n = 66)
Number of subjects: 211
Study 27716211 — intervention group
Group type: COMPARATOR
Intervention: Gene score (GS) in UK healthy men (n = 1360)
Number of subjects: 211
Study 24335055 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU (20 μg) vitamin D₃
Number of subjects: 76
Study 24335055 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU (50 μg) vitamin D₃
Number of subjects: 76
Study 24335055 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU (100 μg) vitamin D₃
Number of subjects: 76
Study 24335055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 23099311 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit dosage interval (6 ML by mouth every 12 hours)
Number of subjects: 193
Study 23099311 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit dosage interval (6 ML by mouth at 7 AM and 7 PM)
Number of subjects: 193
Study 20145273 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose imatinib (800 mg/day for 6 months followed by 400 mg/day as maintenance therapy)
Number of subjects: 227
Study 20145273 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose imatinib (400 mg/day)
Number of subjects: 227
Study 18330677 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 20 mg
Number of subjects: 352
Study 18330677 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg
Number of subjects: 352
Study 18330677 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 80 mg
Number of subjects: 352
Study 18330677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 15793191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 3234
Study 15793191 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 3234
Study 15793191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3234
Study 12220050 — intervention group
Group type: EXPERIMENTAL
Intervention: Provision of cognitively stimulating activities (HOME scales)
Number of subjects: 493
Study 12220050 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal emotional distress
Number of subjects: 493
Study 12220050 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting practices (authoritative and authoritarian behavior)
Number of subjects: 493
Study 10664054 — intervention group
Group type: EXPERIMENTAL
Intervention: dimenhydrinate suppositories
Number of subjects: 99
Study 10664054 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 99
Study 10664054 — intervention group
Group type: EXPERIMENTAL
Intervention: bimedial Faden operation (BMF)
Number of subjects: 99
Study 10664054 — intervention group
Group type: COMPARATOR
Intervention: horizontal recess-resect procedure (R&R)
Number of subjects: 99
Study 8878243 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg on Day 1, followed by 5 mg/kg once daily for 4 days)
Number of subjects: 263
Study 8878243 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (approximately 40 mg/kg/day in 3 divided doses for 10 days)
Number of subjects: 263
Study 1985163 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous continuous infusions of MTX and VM‐26
Number of subjects: 23
Study 1985163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential continuous infusions of MTX and VM‐26
Number of subjects: 23
Study 1985163 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 23
Study 6315120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 308
Study 6315120 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 308
Study 6315120 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole and Cefotaxime
Number of subjects: 308
Study 6315120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime or Metronidazole and Cefotaxime
Number of subjects: 308
Study 31234639 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Channel Blockers (CCBs)
Number of subjects: 0
Study 31234639 — intervention group
Group type: COMPARATOR
Intervention: Nondihydropyridine CCBs
Number of subjects: 0
Study 31234639 — intervention group
Group type: COMPARATOR
Intervention: Dihydropyridine CCBs
Number of subjects: 0
Study 31234639 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitors and β-blockers
Number of subjects: 0
Study 28691885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitusiran (0.225, 0.45, 0.9, or 1.8 mg/kg or fixed dose of 80 mg, once monthly)
Number of subjects: 29
Study 28691885 — intervention group
Group type: COMPARATOR
Intervention: Fitusiran (0.03 mg/kg, single subcutaneous injection)
Number of subjects: 29
Study 28691885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitusiran (0.015, 0.045, or 0.075 mg/kg, once weekly)
Number of subjects: 29
Study 28691885 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitusiran (once monthly)
Number of subjects: 29
Study 25135064 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly interactive HIV and STI education program
Number of subjects: 101
Study 25135064 — intervention group
Group type: COMPARATOR
Intervention: Non-interactive, lecture-based program
Number of subjects: 101
Study 23364237 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate (100 mg, tid)
Number of subjects: 176
Study 23364237 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg, qd)
Number of subjects: 176
Study 21283148 — intervention group
Group type: EXPERIMENTAL
Intervention: Device closure of PFO
Number of subjects: 0
Study 21283148 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 19593174 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 163
Study 19593174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163